About this Journal Submit a Manuscript Table of Contents
Chemotherapy Research and Practice
Volume 2011 (2011), Article ID 730360, 12 pages
http://dx.doi.org/10.1155/2011/730360
Review Article

Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer

Department of Medical Oncology/Hematology, Cancer Center, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

Received 1 November 2010; Revised 4 March 2011; Accepted 16 June 2011

Academic Editor: J. B. Vermorken

Copyright © 2011 Toru Mukohara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. McPherson, C. M. Steel, and J. M. Dixon, “ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics,” British Medical Journal, vol. 321, no. 7261, pp. 624–628, 2000. View at Scopus
  2. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Scopus
  3. D. J. Slamon, W. Godolphin, L. A. Jones et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 707–712, 1989. View at Scopus
  4. D. J. Slamon, G. M. Clark, S. G. Wong, et al., “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Scopus
  5. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. H. J. Burstein, A. Keshaviah, A. D. Baron et al., “Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study,” Cancer, vol. 110, no. 5, pp. 965–972, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Jahanzeb, J. E. Mortimer, F. Yunus et al., “Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer,” Oncologist, vol. 7, no. 5, pp. 410–417, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Von Minckwitz, A. Du Bois, M. Schmidt et al., “Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 1999–2006, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. Slamon, W. Eiermann, N. Robert, et al., “Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2006.
  12. D. Slamon, W. Eiermann, N. Robert, et al., “Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: third planned efficacy analysis,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2009.
  13. E. A. Perez, E. H. Romond, V. J. Suman, et al., “Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer,” Journal of Clinical Oncology, vol. 25, no. 18S, p. 512, 2007.
  14. I. Smith, M. Procter, R. D. Gelber et al., “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial,” The Lancet, vol. 369, no. 9555, pp. 29–36, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. H. Joensuu, P. Bono, V. Kataja et al., “Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5685–5692, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. H. Joensuu, P. L. Kellokumpu-Lehtinen, P. Bono et al., “Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer,” The New England Journal of Medicine, vol. 354, no. 8, pp. 809–820, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. F. Lonardo, E. Di Marco, C. R. King et al., “The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand,” New Biologist, vol. 2, no. 11, pp. 992–1003, 1990. View at Scopus
  19. J. H. Pierce, P. Arnstein, E. DiMarco et al., “Oncogenic potential of erbB-2 in human mammary epithelial cells,” Oncogene, vol. 6, no. 7, pp. 1189–1194, 1991. View at Scopus
  20. C. Wallasch, F. U. Weiss, G. Niederfellner, B. Jallal, W. Issing, and A. Ullrich, “Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3,” EMBO Journal, vol. 14, no. 17, pp. 4267–4275, 1995. View at Scopus
  21. K. Zhang, J. Sun, N. Liu et al., “Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2,” Journal of Biological Chemistry, vol. 271, no. 7, pp. 3884–3890, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Pinkas-Kramarski, A. E. G. Lenferink, S. S. Bacus et al., “The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin,” Oncogene, vol. 16, no. 10, pp. 1249–1258, 1998. View at Scopus
  23. M. Alimandi, A. Romano, M. C. Curia et al., “Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas,” Oncogene, vol. 10, no. 9, pp. 1813–1821, 1995. View at Scopus
  24. M. Tan, J. Yao, and D. Yu, “Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities,” Cancer Research, vol. 57, no. 6, pp. 1199–1205, 1997. View at Scopus
  25. D. Yu, B. Liu, M. Tan, J. Li, S. S. Wang, and M. C. Hung, “Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms,” Oncogene, vol. 13, no. 6, pp. 1359–1365, 1996. View at Scopus
  26. C. Knuefermann, Y. Lu, B. Liu et al., “HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells,” Oncogene, vol. 22, no. 21, pp. 3205–3212, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. D. C. Allred, G. M. Clark, A. K. Tandon et al., “HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma,” Journal of Clinical Oncology, vol. 10, no. 4, pp. 599–605, 1992. View at Scopus
  28. B. A. Gusterson, R. D. Gelber, A. Goldhirsch, et al., “Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group,” Journal of Clinical Oncology, vol. 10, no. 7, pp. 1049–1056, 1992.
  29. T. Holbro, R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas, and N. E. Hynes, “The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8933–8938, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. S. Ménard, S. M. Pupa, M. Campiglio, and E. Tagliabue, “Biologic and therapeutic role of HER2 in cancer,” Oncogene, vol. 22, no. 43, pp. 6570–6578, 2003. View at Scopus
  31. I. Rubin and Y. Yarden, “The basic biology of HER2,” Annals of Oncology, vol. 12, supplement 1, pp. S3–S8, 2001. View at Scopus
  32. T. T. Junttila, R. W. Akita, K. Parsons et al., “Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941,” Cancer Cell, vol. 15, no. 5, pp. 429–440, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. S. T. Lee-Hoeflich, L. Crocker, E. Yao et al., “A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy,” Cancer Research, vol. 68, no. 14, pp. 5878–5887, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami, “Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines,” Annals of Oncology, vol. 21, no. 2, pp. 255–262, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. K. Berns, H. M. Horlings, B. T. Hennessy et al., “A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer,” Cancer Cell, vol. 12, no. 4, pp. 395–402, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. Y. Nagata, K. H. Lan, X. Zhou et al., “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients,” Cancer Cell, vol. 6, no. 2, pp. 117–127, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. K. S. Albain, W. E. Barlow, P. M. Ravdin et al., “Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 374, no. 9707, pp. 2055–2063, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Howell, J. Cuzick, M. Baum, et al., “Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer,” The Lancet, vol. 365, no. 9453, pp. 60–62, 2005.
  41. E. A. Perez, V. J. Suman, N. E. Davidson, et al., “Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2009.
  42. E. A. Perez, M. M. Reinholz, A. C. Dueck, et al., “Do the ASCO/CAP 2007 HER2 testing guidelines improve prediction of benefit to adjuvant trastuzumab? Data from North Central Cancer Treatment Group N9831 Adjuvant Trial,” in Proceedings of the Annual San Antonio Breast Cancer Symposium, San Antonio, Tex, USA, December 2009.
  43. L. G. Gianni, U. Dafni, R. D. Gelber, et al., “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial,” The Lancet Oncology, vol. 12, no. 3, pp. 236–244, 2011.
  44. M. Spielmann, H. Roché, T. Delozier et al., “Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial,” Journal of Clinical Oncology, vol. 27, no. 36, pp. 6129–6134, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. C. Wolff, M. E. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 1, pp. 18–43, 2007. View at Scopus
  46. A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thürlimann, and H. J. Senn, “Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009,” Annals of Oncology, vol. 20, no. 8, pp. 1319–1329, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. M. Gonzalez-Angulo, J. K. Litton, K. R. Broglio et al., “High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5700–5706, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. G. Curigliano, G. Viale, V. Bagnardi et al., “Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5693–5699, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. B. Norris, S. Chia, and M. Cheang, “Poor 10 yr breast cancer specific survival and relapse free survival for HER2 positive T1N0 tumors,” in Proceedings of the Annual San Antonio Breast Cancer Symposium (SABCS '09), San Antonio, Tex, USA, December 2006.
  50. S. Banerjee and I. E. Smith, “Management of small HER2-positive breast cancers,” The Lancet Oncology, vol. 11, no. 12, pp. 1193–1199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. M. S. Ewer and S. M. Lippman, “Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 2900–2902, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. M. S. Ewer, M. T. Vooletich, J. B. Durand et al., “Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7820–7826, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. S. M. Ewer and M. S. Ewer, “Cardiotoxicity profile of trastuzumab,” Drug Safety, vol. 31, no. 6, pp. 459–467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Tan-Chiu, G. Yothers, E. Romond et al., “Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7811–7819, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. E. A. Perez, V. J. Suman, N. E. Davidson et al., “Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial,” Journal of Clinical Oncology, vol. 26, no. 8, pp. 1231–1238, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. M. Y. Halyard, T. M. Pisansky, A. C. Dueck et al., “Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2638–2644, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. B. Kaufman, J. R. Mackey, M. R. Clemens et al., “Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study,” Journal of Clinical Oncology, vol. 27, no. 33, pp. 5529–5537, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. D. W. Rusnak, K. Lackey, K. Affleck et al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 1, no. 2, pp. 85–94, 2001. View at Scopus
  59. G. E. Konecny, M. D. Pegram, N. Venkatesan et al., “Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells,” Cancer Research, vol. 66, no. 3, pp. 1630–1639, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. W. Xia, L. H. Liu, P. Ho, and N. L. Spector, “Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016,” Oncogene, vol. 23, no. 3, pp. 646–653, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. M. Scaltriti, F. Rojo, A. Ocaña et al., “Expression of p95HER2, a truncated form of the HER2 receptor, and response to Anti-HER2 therapies in breast cancer,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 628–638, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. D. Cameron, M. Casey, M. Press et al., “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 533–543, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. N. U. Lin, L. A. Carey, M. C. Liu, et al., “Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer,” Journal of Clinical Oncology, vol. 24, no. 18S, p. 503, 2006.
  64. E. A. Perez, M. Koehler, J. Byrne, A. J. Preston, E. Rappold, and M. S. Ewer, “Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials,” Mayo Clinic Proceedings, vol. 83, no. 6, pp. 679–686, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. W. Xia, C. M. Gerard, L. Liu, N. M. Baudson, T. L. Ory, and N. L. Spector, “Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells,” Oncogene, vol. 24, no. 41, pp. 6213–6221, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. M. Scaltriti, C. Verma, M. Guzman et al., “Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity,” Oncogene, vol. 28, no. 6, pp. 803–814, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. K. L. Blackwell, H. J. Burstein, A. M. Storniolo et al., “Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1124–1130, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. B. Moy and P. E. Goss, “Lapatinib: current status and future directions in breast cancer,” Oncologist, vol. 11, no. 10, pp. 1047–1057, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. C. L. Vogel, M. A. Cobleigh, D. Tripathy et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 719–726, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Paik, J. Bryant, E. Tan-Chiu et al., “Rela-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience,” Journal of the National Cancer Institute, vol. 94, no. 11, pp. 852–854, 2002. View at Scopus
  71. S. Paik, C. Kim, and N. Wolmark, “HER2 status and benefit from adjuvant trastuzumab in breast cancer,” The New England Journal of Medicine, vol. 358, no. 13, pp. 1409–1411, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. F. L. Baehner, N. Achacoso, T. Maddala et al., “Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4300–4306, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. D. B. Agus, R. W. Akita, W. D. Fox et al., “Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth,” Cancer Cell, vol. 2, no. 2, pp. 127–137, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Baselga, K. A. Gelmon, S. Verma et al., “Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1138–1144, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. G. D. Lewis Phillips, G. Li, D. L. Dugger et al., “Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate,” Cancer Research, vol. 68, no. 22, pp. 9280–9290, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. C. L. Vogel, H. A. Burris, S. Limentani, et al., “A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): final results,” Journal of Clinical Oncology, vol. 27, abstract 1017, supplement, p. 15s, 2009.
  77. H. Bernhard, L. Salazar, K. Schiffman et al., “Vaccination against the HER-2/neu oncogenic protein,” Endocrine-Related Cancer, vol. 9, no. 1, pp. 33–44, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. G. E. Peoples, J. P. Holmes, M. T. Hueman et al., “Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group study I-01 and I-02,” Clinical Cancer Research, vol. 14, no. 3, pp. 797–803, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus